亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

A phase III, randomized, double-blind, multicenter study to compare the efficacy, safety, pharmacokinetics, and immunogenicity between SB8 (proposed bevacizumab biosimilar) and reference bevacizumab in patients with metastatic or recurrent nonsquamous non-small cell lung cancer

医学 贝伐单抗 生物仿制药 药代动力学 免疫原性 肿瘤科 内科学 双盲 临床研究阶段 临床试验 化疗 抗体 病理 免疫学 替代医学 安慰剂
作者
Martin Reck,Alexander Valerievich Luft,Igor Bondarenko,Serhii Shevnia,Dmytro V. Trukhin,Nadezhda Vitalievna Kovalenko,K Vacharadze,Andrea Fülöp,A. O. Hontsa,Ji Hye Choi,Donghoon Shin
出处
期刊:Lung Cancer [Elsevier BV]
卷期号:146: 12-18 被引量:25
标识
DOI:10.1016/j.lungcan.2020.05.027
摘要

OBJECTIVES: Efficacy, safety, pharmacokinetics (PK), and immunogenicity of the biosimilar candidate SB8 was compared to its reference product bevacizumab (BEV) in patients with metastatic or recurrent nonsquamous non-small cell lung cancer. METHODS: Patients were randomized (1:1) in a phase III, double-blind study to receive intravenous SB8 or BEV 15 mg/kg with paclitaxel/carboplatin every 3 weeks for 24 weeks, followed by SB8 or BEV maintenance monotherapy. The primary endpoint was best overall response rate (ORR) by 24 weeks. Secondary endpoints included survival outcomes, safety, PK, and immunogenicity. RESULTS: 763 patients (SB8, n = 379; BEV, n = 384) were randomized; baseline characteristics were well balanced. Best ORR in the FAS was 47.6% and 42.8%, and best ORR in the PPS was 50.1% and 44.8% for SB8 and BEV, respectively. The risk ratio of best ORR was 1.11 (90% CI, 0.975-1.269), and the risk difference in best ORR was 5.3% (95% CI, -2.2%-12.9%). Median survival outcomes were comparable between SB8 and BEV: progression-free survival was 8.50 vs 7.90 months, respectively (HR [95% CI], 0.99 [0.83-1.18]; p = 0.9338); overall survival was 14.90 vs 15.80 months, respectively (HR [95% CI], 1.03 [0.83-1.28]; p = 0.7713); and duration of response was 7.70 vs 7.00 months, respectively (HR [95% CI], 1.05 [0.81-1.37]; p = 0.6928). Severity and incidence of treatment-emergent adverse events, PK, and immunogenicity were comparable between SB8 and BEV. CONCLUSION: This study demonstrated equivalence between SB8 and BEV in terms of best ORR risk ratio, with comparable safety, PK, and immunogenicity.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
3秒前
5秒前
闪闪雍完成签到,获得积分10
7秒前
10秒前
10秒前
ccc完成签到,获得积分10
13秒前
好好学习发布了新的文献求助10
14秒前
SciGPT的应助被李糯的饺子采纳,获得10
25秒前
好好学习完成签到,获得积分10
25秒前
俭朴的鸿完成签到,获得积分10
27秒前
33秒前
elfriede完成签到 ,获得积分10
35秒前
沉默的樱完成签到,获得积分10
39秒前
悦耳安萱完成签到 ,获得积分10
43秒前
孙元完成签到 ,获得积分10
50秒前
仰勒完成签到 ,获得积分10
54秒前
57秒前
1分钟前
1分钟前
开心的筮完成签到,获得积分10
1分钟前
1分钟前
lb001完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
Jasper的应助被村口烫头祁师傅采纳,获得10
1分钟前
Liu完成签到,获得积分10
1分钟前
anew_tape发布了新的文献求助10
1分钟前
1分钟前
1分钟前
勤劳晋鹏完成签到,获得积分10
1分钟前
重要静柏完成签到,获得积分10
1分钟前
1分钟前
笑点低的咖啡完成签到,获得积分10
1分钟前
null的应助被teyr采纳,获得10
1分钟前
彭于晏的应助被笑点低的咖啡采纳,获得10
1分钟前
christy完成签到,获得积分20
1分钟前
1分钟前
null的应助被teyr采纳,获得10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165968
求助须知:如何正确求助?哪些是违规求助? 9559396
关于积分的说明 21749984
捐赠科研通 7756746
什么是DOI,文献DOI怎么找? 3429092
关于科研通互助平台的介绍 2553386
邀请新用户注册赠送积分活动 2473667